US Patent

US9108973 — 3,5-disubstituted alkynylbenzene compound and salt thereof

Method of Use · Assigned to Taiho Pharmaceutical Co Ltd · Expires 2033-02-13 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a compound represented by Formula (I) and its salts, as defined in the specification.

USPTO Abstract

The present invention provides a compound represented by Formula (I) (wherein R 1 , X 1 , X 2 , Y, and Z are as defined in the specification), or a salt thereof.

Drugs covered by this patent

Lytgobi (futibatinib) · Taiho Oncology

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3456`	—	Lytgobi
`U-3456`	—	Lytgobi

Patent Metadata

Patent number: US9108973
Jurisdiction: US
Classification: Method of Use
Expires: 2033-02-13
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Taiho Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.